An imaging test that measures the function of estrogen receptors in breast cancer cells can distinguish patients likely or unlikely to benefit from hormone therapy, a new study shows.
Hormone therapy is commonly given as a targeted treatment for women whose cancer cells carry receptors for estrogen. But the therapy only works for about half of all patients. Until now, there hasn’t been a good way to reliably predict who will benefit and who will not.
In a small phase 2 clinical trial, researchers showed that the cancers of all patients with working estrogen receptors remained stable or improved on hormone therapy, and progressed in all women with nonfunctional estrogen receptors.
Emerson names top executive Karsanbhai as new CEO
DUBAI, February 7, 2021 Emerson, a global automation technology and industrial software leader, has announced that Lal Karsanbhai, who has served as executive president of the company’s automation solutions business since 2018, will step in as the company’s new chief executive officer as David N. Farr retired on February 5, 2021. Karsanbhai, who has led the Automation Solutions to strong performance, elevating Emerson’s software profile and digital transformation business will also join the board of directors. Farr, who was named CEO in 2000 and chairman of Emerson’s board of directors in 2004, will remain as chairman through May 4.
Emerson names Karsanbhai as new CEO
DUBAI, February 7, 2021 Emerson, a global automation technology and industrial software leader, announced that Lal Karsanbhai, who has served as executive president of the company’s Automation Solutions business since 2018, will step in as the company’s new chief executive officer as David N. Farr retired on February 5, 2021. Karsanbhai, who has led the Automation Solutions to strong performance, elevating Emerson’s software profile and digital transformation business will also join the board of directors. Farr, who was named CEO in 2000 and chairman of Emerson’s board of directors in 2004, will remain as chairman through May 4. Over his two decades at the helm of the $16.8 billion global company, Farr has led Emerson through multiple strategic evolutions to grow the company’s global footprint, stay ahead of changing market conditions and advance the organisation’s capabilities and competitiveness on the worldwide sta
IP Architects
John P. Pironti is the President of IP Architects, LLC. He has designed and implemented enterprise wide electronic business solutions, information security and risk management strategy and programs, enterprise resiliency capabilities, and threat and vulnerability management solutions for key customers in a range of industries, including financial services, insurance, energy, government, hospitality, aerospace, healthcare, pharmaceuticals, media and entertainment, and information technology on a global scale for over 25 years. Seth Geftic Sophos
Seth is a Director at Sophos focusing on endpoint security. Prior to joining Sophos he was a Director of Product Marketing at Invincea (acquired by Sophos in 2017). Seth was previously a Senior Manager in the Advanced Security Operations Center (SOC) Solution group and the cybercrime team at RSA. He is an industry expert in fields of endpoint security, breach detection, incident response, fraud, and cyber threats. Seth
Longtime Merck executive Ken Frazier, whose leadership helped bring the drugmaker one of the most lucrative medicines in history and who is one of the few remaining Black CEOs of a major corporation, is retiring.Frazier, Merck’s CEO since early 2011 and an advocate for minority advancement who took on then-President Trump’s tacit support of white supremacists, will retire on June 30.Frazier, 66, will be replaced by Rob Davis, the chief financial officer since 2014, the company said Thursday as it announced quarterly financial results. Frazier will become executive chairman of the board during a transition period. The change comes just months after Dr. Dean Li took over as head of Merck's research and development.